Oncternal Therapeutics Announces First Patient Dosed In Phase 1/2 Study Of Dual-Action AR Inhibitor, ONCT-534, In Patients With Metastatic Castration-Resistant Prostate Cancer
Portfolio Pulse from Benzinga Newsdesk
Oncternal Therapeutics has announced the first patient has been dosed in the Phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor for patients with metastatic castration-resistant prostate cancer. The company plans to advance the dose escalation portion of the study quickly, with patient enrollment across the U.S. and in the U.K. in early 2024. Initial clinical data is expected in the first half of 2024.
October 05, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oncternal Therapeutics has begun a Phase 1/2 study of ONCT-534, a treatment for metastatic castration-resistant prostate cancer. This could potentially open a new revenue stream for the company if the drug proves successful.
The initiation of the Phase 1/2 study of ONCT-534 represents a significant milestone for Oncternal Therapeutics. If the drug proves successful, it could potentially open a new revenue stream for the company. However, the results are not expected until the first half of 2024, so the immediate impact on the stock price may be limited.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100